Appendix 2. Data Collection Form (Adapted from Cochrane Collaboration)

General Information

Date form completed	
Name of reviewer extracting data	
Contact details of reviewer extracting data	
Title of publication	
Publication ID (first author and year of publication)	
Country in which study was conducted	
Study funding source	
Possible conflicts of interests for study authors	

Primary Study Details

1. Methods

Study Characteristics	Review Inclusion Criteria
Design (Type of randomized trial)	Blinded vs non-blinded
	Cross-over present
Method(s) of recruitment of participants	
Unit of allocation (individual vs cluster/group)	
Clinical setting	Pre-hospital vs Emergency Department vs Hospital
Types of intervention	Different dosing regimens of transdermal GTN

Types of comparator	Standard therapy vs placebo
Types of outcome measures	Primary:
	Secondary:
	Safety:

2. Study Population and Setting

Study population description	Stroke subtypes: haemorrhagic vs ischaemic
	Stroke onset to randomization
	Other stroke subgroups (like IV thrombolytics, etc)
Inclusion criteria	
Exclusion criteria	
Start date	
End date	
Duration of participation (recruitment to last follow-up)	

3. Participants (in intervention vs control/placebo groups)

Total number of individuals randomized	Intervention group:	
	Control/ placebo group:	
Total number of clusters randomized (if applicable)	Intervention group:	
	Control/ placebo group:	
Number of withdrawals/exclusions	Intervention group:	
	Control/ placebo group:	
Number of cross-overs	Intervention group:	

	Control/ placebo group:
Baseline imbalances	
Other treatments (apart from intervention vs control/placebo)	Intervention group:
	Control/ placebo group:
Subgroups measured	
Subgroups reported	

4. Outcomes (create a separate section for each outcome)

Outcome name	
Outcome type (Primary vs secondary vs safety)	
Time points when outcome was measured (from start or at end of intervention or control/placebo)	
Time points reported	
Outcome definition	
Method(s) of outcome assessment (using any tool/scale, etc)	
Is the outcome assessment tool validated?	
Persons measuring and /or reporting outcome	
Imputation of missing data	
Analysis via intention-to-treat or per- protocol or both	

5. Results (create a separate section for each outcome)

Ulicome	
	•

Dichotomous or continuous	
Subgroup	
Time point	
Results (may have more than two arms)	Intervention group:
	Control/placebo group
Number of missing participants	Intervention group:
	Control/placebo group:
Number of cross-over	Intervention group:
	Control/placebo group:
Statistical methods used and appropriateness of these methods	

Risk of Bias Assessment (create a separate section for each outcome)

Domain	Risk of bias (High/Low/Unclear)	Support for Judgement
Random sequence generation (selection bias)		
Allocation concealment (selection bias)		
Blinding of participants and personnel (performance bias)		
Blinding of outcome assessment (detection bias)		
Incomplete outcome data (attrition bias)		

Selective outcome	
reporting	
(reporting bias)	
<u> </u>	
Other bias	